Your AI-Trained Oncology Knowledge Connection!
Most ongoing clinical trials exploring nectin-4 as a target involve studies of enfortumab vedotin and its potential synergy with immune checkpoint inhibitors in bladder cancer, while several other early-phase studies are testing novel agents in solid tumors.
Oleg Bess, MD, explains why data quality is essential to improving the United States health care system.
The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.
Stephen Johnston, MD, PhD, provides insight on the effect the approval of the CDK4/6 inhibitor abemaciclib has for patients with early breast cancer and how it will advance investigative efforts in this space.
During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts shared their insights on the most recent FDA-approved agents for MDS, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020.
Peter Schmid, MD, PhD, discussed how this approval defines a new standard of care for patients with TNBC.
Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.
